Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NYSE:DPLO

Diplomat Pharmacy (DPLO) Stock Price, News & Analysis

Diplomat Pharmacy logo

About Diplomat Pharmacy Stock (NYSE:DPLO)

Key Stats

Today's Range
$4.00
$4.01
50-Day Range
$4.00
$4.00
52-Week Range
$2.43
$14.46
Volume
744,968 shs
Average Volume
545,194 shs
Market Capitalization
$304 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company primarily focuses on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. It also offers PBM services, including electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, drug review and analysis, consulting services, data access, and reporting, information analysis, and preferred drug management programs to managed care organizations, self-insured employer groups, unions, and third-party healthcare plan administrators and worker's compensation payers. The company was founded in 1975 and is headquartered in Flint, Michigan.

Receive DPLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diplomat Pharmacy and its competitors with MarketBeat's FREE daily newsletter.

DPLO Stock News Headlines

Trump said you could learn something from this man
Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.
See More Headlines

DPLO Stock Analysis - Frequently Asked Questions

Diplomat Pharmacy Inc (NYSE:DPLO) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($2.35) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $2.15. The business's revenue for the quarter was down 5.3% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Diplomat Pharmacy investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Cara Therapeutics (CARA), Cannabis Sativa (CBDS), CVS Health (CVS) and Jazz Pharmaceuticals (JAZZ).

Company Calendar

Last Earnings
11/12/2019
Today
11/21/2024

Industry, Sector and Symbol

Industry
Drug Stores & Proprietary Stores
Sub-Industry
N/A
Fax
N/A
Employees
2,335
Year Founded
N/A

Profitability

Net Income
$-302,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.49 billion
Cash Flow
$4.60 per share
Book Value
$6.24 per share

Miscellaneous

Free Float
N/A
Market Cap
$304 million
Optionable
Optionable
Beta
0.82
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NYSE:DPLO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners